The estimated Net Worth of Aristippos Gennadios is at least $7.48 Million dollars as of 2 August 2024. Aristippos Gennadios owns over 1,169 units of Catalent stock worth over $6,781,362 and over the last 10 years he sold CTLT stock worth over $694,343. In addition, he makes $0 as President - Softgel Technologies at Catalent.
Aristippos has made over 14 trades of the Catalent stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,169 units of CTLT stock worth $69,614 on 2 August 2024.
The largest trade he's ever made was exercising 123,880 units of Catalent stock on 25 November 2019 worth over $2,273,198. On average, Aristippos trades about 6,470 units every 90 days since 2015. As of 2 August 2024 he still owns at least 113,724 units of Catalent stock.
You can see the complete history of Aristippos Gennadios stock trades at the bottom of the page.
Dr. Aristippos Gennadios Ph.D. is President - Softgel Technologies of the Company. Dr. Gennadios has served as our President, Softgel Technologies since September 2013. Previously, he served as Vice President and General Manager of Softgel Technologies. Dr. Gennadios has worked in the pharmaceutical industry since 1996 in roles including R&D, field sales, business development, operations and leadership. He joined our predecessor company, Cardinal Health, in 2002 and has held several key leadership posts within the softgel technologies business, including Global Vice President of Business Development for Softgel Technologies, General Manager of the Oral Development Center in Somerset, NJ, and Vice President and General Manager for Prescription Softgel and Consumer Health products. Dr. Gennadios holds a bachelor’s degree in chemical engineering from the National Technical University of Athens, Greece and a master’s degree in agricultural engineering from Clemson University. He also holds a doctorate in engineering from the University of Nebraska and an M.B.A. from Wake Forest University.
Aristippos Gennadios is 54, he's been the President - Softgel Technologies of Catalent since 2013. There are 16 older and 11 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Aristippos's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius und Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: